# Do all patients who have prostate cancer with seminal vesicle invasion have poor prognosis?

Yoshinori Yanai, Takeo Kosaka, Hiroshi Hongo, Yota Yasumizu, Nobuyuki Tanaka, Toshikazu Takeda, Kazuhiro Matsumoto, Shinya Morita, Ryuichi Mizuno, Mototsugu Oya

### Introduction and objectives

Postoperative adjuvant radiation therapy (RTx) after radical prostatectomy (RP) is usually recommended in patients with seminal vesicle invasion (SVI) who have an expected survival of  $\geq$ 15 years [1][2]. However, the optimal timing of postoperative RTx is unclear and controversial.

In the Radiotherapy - Adjuvant Versus Early Salvage (RAVES) trial, it remains unclear if adjuvant RTx is superior to observation with early salvage RTx for local control and BCR-free survival [3].



	PSA recurrence		Univariat
	No	Yes	p-value
Age (yr)			0.115
<66	16	8	
≧66	20	23	
PSA (ng/ml)			0.007
<10	27	11	
10-20	7	13	
>20	2	6	
clinical T stage			0.676
cT1c, 2a, 2b	24	22	
cT2c, 3a	11	8	
Grade Group			0.215
1, 2	9	4	
3, 4, 5	27	27	
Extraprostatic extension			0.007
No	14	3	
Yes	22	28	
Positive surgical margin			0.100
No	15	7	
Yes	21	24	

Department of Urology, Keio University School of Medicine

## Methods

We retrospectively reviewed the clinicopathological data of 1240 consecutive patients who underwent RP between 2005 and 2018. Patients receiving adjuvant therapy were excluded. Multiple variables were evaluated as the predictors for the biochemical recurrence (BCR) after RP.

Previous reports which adjuvant RTx was associated with reduced BCR compared with early salvage RTx were randomized trials [4][5]. In these studies, the cases of SVI were excluded. To our knowledge, there were no reports regarding combination with SVI and EPE.

[1] Han M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517–23 [2] Bolla M, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer : long-term results of a randomised controlled trial (EORTC trial 22911) Lancet. 2012; 380:2018-27. [3] Pearse M, et al. A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: Background and rationale of the Radiotherapy - Adjuvant Versus Early Salvage (RAVES)

[4] Hwang WL, et al. Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol 2018;4:e175230. [6] Ohori M, et al. The mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. Am J Surg Pathol. 1993;17(12):1252-61.



→_ Negati	ve extrapr	ostatic ext	tension
L	+ +		+
· • - • • • • • • • • • • • • • • •	+-, , '-+	• +	+ + + +
Positiv	e extrapro	ostatic exte	ension
48	72	96	120

